title: Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
authors.forename: S H
authors.initials: SH
authors.lastname: Sheingold
authors.forename: D N
authors.initials: DN
authors.lastname: Churchill
authors.forename: N
authors.initials: N
authors.lastname: Muirhead
authors.forename: A
authors.initials: A
authors.lastname: Laupacis
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001803:Blood Transfusion / Q000191:economics; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007676:Kidney Failure, Chronic / Q000150:complications / Q000191:economics*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D012959:Socioeconomic Factors
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin